Gary E. Landreth

Therapeutic Targeting of Microglial Hexokinase-2 Recalibrates Inflammasome Activation and Improves Functional Recovery After Traumatic Brain Injury

Alzheimer-related pathogenesis is dependent on neuronal receptor PTPσ.

This study identifies PTPσ as a critical regulator of Alzheimer-related pathologies by modulating APP proteolytic metabolism and downstream pathogenic processes.

Functional 3'-UTR Variants Identify Regulatory Mechanisms Impacting Alcohol Use Disorder and Related Traits

The paper identifies functional 3'-UTR variants linked to alcohol use disorder and related traits using MPRA and GWAS integration.

Therapeutic targeting of immunometabolism in Alzheimers disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression.

This study shows that reducing Hexokinase 2 (HK2) in microglia slows Alzheimer's disease progression, but complete loss worsens inflammation, suggesting a complex role for HK2 in neuroinflammation.

Genetic Variants of Phospholipase C-γ 2 Confer Altered Microglial Phenotypes and Differential Risk for Alzheimers Disease

The paper identifies a PLCG2 variant, PLCG2M28L, associated with increased Alzheimer's disease risk and altered microglial phenotypes, while another variant, PLCG2P522R, reduces disease risk in a mouse model.

INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia

This study shows INPP5D expression increases in Alzheimer's disease, particularly in plaque-associated microglia, and suggests it may be a risk factor and therapeutic target.

PLCG2 as a Risk Factor for Alzheimer's Disease

The paper identifies a rare PLCG2 variant that increases Alzheimer's disease risk and shows increased PLCG2 expression correlates with amyloid deposition in AD patients.